In recent years,infections caused by macrolide-resistant Mycoplasma pneumoniae(MRMP)have garnered widespread attention.Concurrently,there has been a notable increase in the incidence of severe and refractory Mycoplasma pneumoniae pneumonia(MPP),posing significant challenges to clinical diagnostic and therapeutic practices.The early identification and intervention of severe and critical cases to prevent mortality and sequelae have become a formidable challenge and an important issue for pediatricians.Among these,the judicious application of anti-infective and anti-inflammatory drugs in the early stages is key for improving prognosis.This article aims to provide an review on the anti-infective and anti-inflammatory treatment strategies for MPP.
万方数据